By Electronic Mail. Ouachita Medical Properties, L.C. 000 Xxxx Xxxxxx Xxxxxx, XX 00000 Attention: Xxxxx Xxxxxxxx Tel. No.: (000) 000-0000 Email: xxxxxxxxxx@xxx.xxx Re: Agreement for Purchase and Sale of Real Property, having an effective date of May 21, 2013, by and between American Realty Capital V, LLC, a Delaware limited liability company (together with its successors and assigns, “Buyer”), and Ouachita Medical Properties, L.C., a Louisiana limited liability company (“Seller), as amended by letter agreement, having an effective date of June 20, 2013, by and between Buyer and Seller (as amended, the “Agreement”) Dear Xx. Xxxxxxxx: Reference is made to the Agreement. Capitalized terms used herein but not defined herein shall have the meanings given to such terms in the Agreement. This letter agreement shall serve to memorialize the following matters:
By Electronic Mail. Xx. Xxxxxx Xxxxxx Dear Xxxxxx: This letter agreement (this “Employment Agreement”) sets forth the terms of your employment with Green Dot Corporation (the “Company” or “us”) as the Company’s Executive Vice President, Chief Product, Strategy and Development Officer (“CPO” or “you”). Your service with the Company will be subject to the terms and conditions of this Employment Agreement and shall be effective as of May 6, 2020 (the “Effective Date”), and shall end on the fifth anniversary of the Effective Date, subject to the provisions of Section 8 below.
By Electronic Mail. Xxxxxxx X’Xxxxx, M.D. Dear Xxxxxxx: On behalf of Editas Medicine, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer:
By Electronic Mail. Xx. Xxxxxx Xxxxxxx Dear Xxxxxx: This letter agreement (this “Employment Agreement”) sets forth the terms of your employment with Green Dot Corporation (the “Company” or “us”) as the Company’s Chief Operating Officer and Chief Financial Officer (“COO & CFO” or “you”). Your service with the Company will be subject to the terms and conditions of this Employment Agreement and shall be effective as of October 21, 2021 (the “Effective Date”), and shall end on the fifth anniversary of the Effective Date, subject to the provisions of Section 8 below. Upon the Effective Date and during the Term of this Agreement, the Company will use its reasonable best efforts to have the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Company’s Board of Directors (the “Board”) nominate you to serve as a member of the Board and to renominate you each year that you are slated for reelection, unless or until you are not elected to the Board at any annual meeting of the Company’s stockholders.
By Electronic Mail. Xxxxxx X. Xxx, Xx. Xxxxxx, XxXxxxxxx & Auth 000 Xxxxxxxx Xxxxxx Xxxxxxxx, XX 00000 Re: Purchase and Sale Agreement between Charlton Housing Associates Limited Partnership (“Seller”) and CBA Housing Limited Partnership, assignee of HAP, Inc. (“Buyer”) dated August 30, 2006, as amended (the “Purchase Agreement”) Dear Norm: This firm represents Seller and this letter constitutes the escrow instructions of Seller in connection with the closing of the above-referenced transaction.
By Electronic Mail. Xxxxx X. Xxxxxx Dear Xxx: Reference is made to that certain Employment Offer Letter dated February 13, 2021 between Editas Medicine, Inc. (the “Company”), and you regarding the terms of your employment with the Company (the “Offer Letter”). This letter (the “Amendment”), shall be effective June 1, 2022, confirms the agreement between the Company and you regarding an amendment to the Offer Letter.
By Electronic Mail. Xxx Xxxxxx President and CEO Satiogen Pharmaceuticals, Inc. Email: […***…] RE: Amendment to License Agreement entered into on February 8, 2011 by and between Lumena Pharmaceuticals, Inc. and Satiogen Pharmaceuticals, Inc. Dear Rob: We refer to the License Agreement (the “License Agreement”) entered into on February 8, 2011 by and between Lumena Pharmaceuticals, Inc. and Satiogen Pharmaceuticals, Inc. (“Satiogen”). In 2014, Lumena Pharmaceuticals, Inc. became Lumena Pharmaceuticals LLC (“Lumena”). Pursuant to Article 10.4 of the License Agreement, the purpose of this Letter Agreement (“Letter Agreement”) is to amend the License Agreement. Capitalized terms used in this letter not otherwise defined herein will have the meanings given to them in the License Agreement. The effective date of this Letter Agreement (“Effective Date”) is the date of the last signature below. Termination of certain licenses. Lumena hereby terminates all rights granted by the License Agreement to the following Licensed Patents: Hampshire International Business Park Chineham, Basingstoke Hampshire RG24 SEP United Kingdom xxx.xxxxx.xxx Table 1. Licensed Patents subject to this Letter Agreement Patent or Application Number U.S. 8,318,663 U.S. 9,345,715 U.S. 15/136,539 GB 2465677 ZL 200980155866.7 CA 2744697 EP 9829741.9 U.S. 9,339,480 GB 2465879 EP 25758211 CN 20098015584S.9 The rights with respect to the Licensed Patents set forth in Table l that were granted by Satiogen to Lumena pursuant to Article 2 of the License Agreement are hereby terminated and all rights granted therein hereby immediately revert back to Satiogen. Effective immediately, Lumena is no longer responsible for reimbursement to Satiogen for any of the patent preparing, filing, prosecution, and maintenance costs incurred with respect to the Licensed Patents set forth in Table 1.